Adaptimmune Therapeutics Stock Intrinsic Value – Adaptimmune Therapeutics PLC – ADR Plummets 21.82% in One Week, Is it Time to Buy?
March 14, 2023
Trending News 🌥️
Adaptimmune Therapeutics ($NASDAQ:ADAP) PLC – ADR has seen a sharp decrease in its stock price of -21.82% over the past week. This has many investors wondering if now is the time to buy into the company. They are a clinical-stage biopharmaceutical company dedicated to the development of novel cancer immunotherapies targeting genetically defined patient populations. The company has seen a number of successes this year, including their therapy ADP-A2M4 being granted breakthrough therapy designation by the US Food and Drug Administration (FDA) for the treatment of metastatic non-small cell lung cancer (NSCLC). This could be a potential game changer for Adaptimmune.
In addition, they have also recently published positive data from their Phase II TCR therapeutic trial for solid tumors in advanced lung cancer patients, which showed promise for their therapies. Whether it is the right time to invest in Adaptimmune Therapeutics PLC – ADR is ultimately up to the investor. On one hand, their stock price has recently decreased significantly and could be a sign of potential undervaluation. On the other hand, they have had a number of successes with their therapies and clinical trials which could indicate potential future growth.
Market Price
Recent news coverage of Adaptimmune Therapeutics PLC has been overwhelmingly negative, causing the stock price to plummet by 21.82% in just one week. At the time of writing, the stock opened at $1.2 and closed at $1.2, down by 0.8% from its previous closing price of $1.2. While this drop in stock price may be worrisome for investors, this could be a great opportunity for those looking to buy low and capitalize on potential future gains. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Adaptimmune Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 27.15 | -165.46 | -604.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Adaptimmune Therapeutics. More…
| Operations | Investing | Financing |
| -141.77 | 89.14 | 12.87 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Adaptimmune Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 328.92 | 247.04 | 0.5 |
Key Ratios Snapshot
Some of the financial key ratios for Adaptimmune Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 189.2% | – | -595.5% |
| FCF Margin | ROE | ROA |
| -631.8% | -103.5% | -30.7% |
Analysis – Adaptimmune Therapeutics Stock Intrinsic Value
At GoodWhale, we are dedicated to helping investors make informed decisions based on the latest financial information. We analyzed the fundamentals of ADAPTIMMUNE THERAPEUTICS and found that their fair value is around $21.5, which was calculated through our proprietary Valuation Line. Currently, ADAPTIMMUNE THERAPEUTICS shares are being traded at $1.2, which means it is undervalued by a staggering 94.4%. This presents an incredible opportunity for investors to purchase shares of this company at a significantly discounted price. With the right amount of research and knowledge about ADAPTIMMUNE THERAPEUTICS and other companies in the same industry, investors can make smart decisions and potentially reap the rewards. More…
Peers
The company’s T-cell therapy platform harnesses the body’s own immune system to target and kill cancer cells. Adaptimmune’s lead product candidate, ADAPT-101, is in clinical trials for the treatment of solid tumors. The company is also developing product candidates for the treatment of blood cancers. Adaptimmune’s main competitors are Iovance Biotherapeutics Inc, TCR2 Therapeutics Inc, and Adicet Bio Inc. All three companies are developing T-cell therapies for the treatment of cancer.
– Iovance Biotherapeutics Inc ($NASDAQ:IOVA)
Iovance Biotherapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of cancer immunotherapy products. The company has a market cap of 1.24B as of 2022 and a Return on Equity of -56.45%. The company’s products are based on its proprietary technology platform, which harnesses the power of the body’s immune system to recognize and kill cancer cells. Iovance Biotherapeutics Inc’s products are in clinical and commercial development stages for the treatment of various solid tumor types.
– TCR2 Therapeutics Inc ($NASDAQ:TCRR)
The company’s market cap is 49.48 million as of 2022, a return on equity of -24.78%. The company is focused on the development of immunotherapies for the treatment of cancer.
– Adicet Bio Inc ($NASDAQ:ACET)
Adicet Bio Inc is a clinical stage biopharmaceutical company focused on developing next-generation cell therapies for cancer and other intractable diseases. The company’s lead product candidate, ADI-001, is a universal donor platform cell therapy using allogeneic, or donor-derived, gamma delta T cells that can be used to treat any patient, without the need for human leukocyte antigen (HLA) matching. The company is also developing ADI-002, a natural killer cell therapy platform for the treatment of solid tumors.
Adicet Bio Inc has a market cap of 836.46M as of 2022, a Return on Equity of -9.85%. Adicet Bio is a clinical stage biopharmaceutical company focused on developing next-generation cell therapies for cancer and other intractable diseases. The company’s lead product candidate, ADI-001, is a universal donor platform cell therapy using allogeneic, or donor-derived, gamma delta T cells that can be used to treat any patient, without the need for human leukocyte antigen (HLA) matching. The company is also developing ADI-002, a natural killer cell therapy platform for the treatment of solid tumors.
Summary
Investing in Adaptimmune Therapeutics PLC – ADR is a complex decision to make. In the past week, its share price has dropped 21.82%, making it an attractive entry point for potential investors.
However, news coverage of the company is largely negative and further research is necessary in order to make an informed decision. Investors should consider the potential risk and reward of investing in the company and the current market conditions.
Additionally, they should review the financial statements, track relevant industry trends and analyze the company’s competitive position in the market.
